Dendritic Cells from Cord Blood Induce Specific Immunity Against Ovarian Cancer in Vitro

孙丽,孔北华,张昕,马道新,刘春生
DOI: https://doi.org/10.3969/j.issn.1004-0242.2004.01.014
2004-01-01
Abstract:To explore specific immunity against ovarian cancer cell by cord blood-derived dendritic cells (DCs).① Mononuclear cells(MNCs) were obtained from ficoll separated cord blood. The monocytes(Mo) were isolated and cultured in medium with granulocyte-macrophage colony stimulating factor(GM-CSF) and interleukin 4(IL-4). Cells were harvested after 7 days for phenotypic analysis by flow cytometry.② On the 3th day, human ovarian cancer cells 3AO cytolysis antigen was added into medium, in which immature DCs gradually matured and expressed special tumor antigen after 4 days.After this kind of DCs were co-cultured with allogeneic T cells derived from cord blood for 3 days,the T cells were activated to become tumor specific cytotoxic T lymphocytes(CTL).Methyl thiazolyl tetrazolium(MTT) assay was employed to detect inhibition rate of CTL and its supernatant on 3AO cell,HCCC-9810 cells?293T cells, respectively.① The results indicated that DC precursors in cord blood could differentiate to mature DC in medium containing GM-CSF/IL-4 for 7 days.The induced DC had high expression of CD1a,CD80(B7-1) CD83,CD86(B7-2) and HLA-DR. ② Mature DC with tumor cytolysis antigen could activate naive T cells to become tumor specialized CTL.Different cell amounts of CTL and the supernatant had significant inhibition or killing response on 3AO cells (P0.05).[Conclusion]In certain cytokine environment, Mo in cord blood can differentiate to functional DC in vitro, which can activate naive T lymphocyte to CTL and induce specific antitumor immune response.
What problem does this paper attempt to address?